Literature DB >> 22544372

Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC).

Daniel Baumunk1, Uta Reichelt, Jannis Hildebrandt, Hans Krause, Jan Ebbing, Hannes Cash, Kurt Miller, Martin Schostak, Steffen Weikert.   

Abstract

PURPOSE: Metabolic adaptations, such as increases in glucose and energy metabolism, play a pivotal role in the biology of RCC. PDK-1 and DJ-1/PARK7 are thought to control metabolic pathways in cancer. We investigated the expression of PDK-1 and DJ-1/PARK7 in RCC and their prognostic relevance.
METHODS: RCC tumor tissue and corresponding normal parenchyma samples were obtained from 91 patients with clear cell RCC. Expression of PDK-1 and DJ-1/PARK7 was determined on the mRNA and protein levels using quantitative RT-PCR and immunohistochemistry. Expression ratios tumor/normal were analyzed for associations with pathological stage and grade (Kruskal-Wallis ANOVA, chi-square test). Potential associations with progression-free and overall survival were analyzed using Cox regression models.
RESULTS: PDK-1 mRNA expression was up-regulated as compared to normal tissue (p < 0.001). Differences were observed by tumor stage (p < 0.05) with a trend toward lower expression with increasing stage (p > 0.01). Expression ratio tumor/normal also showed differences by tumor stage with the lowest ratio observed in advanced (pT3) disease. MRNA expression data were confirmed on the protein level with the lowest protein expression in pT3 tumors. PDK-1 expression ratio tumor/normal was inversely associated with outcome after adjustment for stage and grade (HR, 0.54; 95 % CI, 0.31-0.94). No associations observed for DJ-1/PARK7 expression.
CONCLUSIONS: PDK is up-regulated in RCC, but down-regulation may be associated with progression toward a metastasizing behavior. Given the role of PDK-1 in the control of glucose metabolism, aerobic glycolysis via up-regulation of PDK-1 may be an early event in RCC development, but less relevant for the progression toward an aggressive phenotype.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544372     DOI: 10.1007/s00345-012-0874-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  24 in total

1.  Energy deregulation: licensing tumors to grow.

Authors:  Ken Garber
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

2.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

3.  Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase.

Authors:  L G Korotchkina; M S Patel
Journal:  J Biol Chem       Date:  2001-08-02       Impact factor: 5.157

4.  Tissue microarrays for gene amplification surveys in many different tumor types.

Authors:  P Schraml; J Kononen; L Bubendorf; H Moch; H Bissig; A Nocito; M J Mihatsch; O P Kallioniemi; G Sauter
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

Review 5.  Misdiagnosis of clear cell renal cell carcinoma.

Authors:  Vladimir A Valera; Maria J Merino
Journal:  Nat Rev Urol       Date:  2011-05-17       Impact factor: 14.432

6.  DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses.

Authors:  Sophie Vasseur; Samia Afzal; Joël Tardivel-Lacombe; David S Park; Juan Lucio Iovanna; Tak Wah Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-14       Impact factor: 11.205

7.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption.

Authors:  Ioanna Papandreou; Rob A Cairns; Lucrezia Fontana; Ai Lin Lim; Nicholas C Denko
Journal:  Cell Metab       Date:  2006-03       Impact factor: 27.287

8.  Identification of DJ-1/PARK-7 as a determinant of stroma-dependent and TNF-alpha-induced apoptosis in MDS using mass spectrometry and phosphopeptide analysis.

Authors:  A Mario Marcondes; Xiang Li; Ted A Gooley; Brian Milless; H Joachim Deeg
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113

9.  Metabolic profiling reveals key metabolic features of renal cell carcinoma.

Authors:  Gareth Catchpole; Alexander Platzer; Cornelia Weikert; Carsten Kempkensteffen; Manfred Johannsen; Hans Krause; Klaus Jung; Kurt Miller; Lothar Willmitzer; Joachim Selbig; Steffen Weikert
Journal:  J Cell Mol Med       Date:  2011-01       Impact factor: 5.310

Review 10.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.

Authors:  E D Michelakis; L Webster; J R Mackey
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

View more
  17 in total

1.  PDK1: a new therapeutic target for glioblastoma?

Authors:  Kiran Kumar Velpula; Andrew J Tsung
Journal:  CNS Oncol       Date:  2014-05

Review 2.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

Review 3.  Metabolism of kidney cancer: from the lab to clinical practice.

Authors:  Sunil Sudarshan; Jose A Karam; James Brugarolas; R Houston Thompson; Robert Uzzo; Brian Rini; Vitaly Margulis; Jean-Jacques Patard; Bernard Escudier; W Marston Linehan
Journal:  Eur Urol       Date:  2012-09-28       Impact factor: 20.096

4.  Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival.

Authors:  Hans Anton Schlößer; Uta Drebber; Alexander Urbanski; Simon Haase; Christoph Baltin; Felix Berlth; Susanne Neiß; Michael von Bergwelt-Baildon; Ulrich Klaus Fetzner; Ute Warnecke-Eberz; Elfriede Bollschweiler; Arnulf Heinrich Hölscher; Stefan Paul Mönig; Hakan Alakus
Journal:  Gastric Cancer       Date:  2015-12-07       Impact factor: 7.370

5.  Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer.

Authors:  Kira T Pate; Chiara Stringari; Stephanie Sprowl-Tanio; Kehui Wang; Tara TeSlaa; Nate P Hoverter; Miriam M McQuade; Chad Garner; Michelle A Digman; Michael A Teitell; Robert A Edwards; Enrico Gratton; Marian L Waterman
Journal:  EMBO J       Date:  2014-05-13       Impact factor: 11.598

Review 6.  Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?

Authors:  Wen Zhang; Shao-Lin Zhang; Xiaohui Hu; Kin Yip Tam
Journal:  Int J Biol Sci       Date:  2015-11-01       Impact factor: 6.580

7.  Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition.

Authors:  Cecilie Abildgaard; Christina Dahl; Astrid L Basse; Tao Ma; Per Guldberg
Journal:  J Transl Med       Date:  2014-09-03       Impact factor: 5.531

8.  Up-regulation of pVHL along with down-regulation of HIF-1α by NDRG2 expression attenuates proliferation and invasion in renal cancer cells.

Authors:  Lei Gao; Guo-jun Wu; Bei Liu; Ming-zhi Shen; Tie-jun Pan; Chui-gong Yu; Qin-hao Wang; Yi Ru; Xi-ping Liu; Tian-shui Niu; Guo-dong Wang; Ming Wei; Rui-xiao Li; Libo Yao; He Wang; Xia Li
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

9.  The Succinated Proteome of FH-Mutant Tumours.

Authors:  Ming Yang; Nicola Ternette; Huizhong Su; Raliat Dabiri; Benedikt M Kessler; Julie Adam; Bin Tean Teh; Patrick J Pollard
Journal:  Metabolites       Date:  2014-08-07

10.  Linking vitamin B1 with cancer cell metabolism.

Authors:  Jason A Zastre; Rebecca L Sweet; Bradley S Hanberry; Star Ye
Journal:  Cancer Metab       Date:  2013-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.